The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in decreased expression of ABCB11 mRNA; Sodium Selenite promotes the reaction [[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in decreased expression of ABCB11 mRNA]
[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in decreased expression of ALB protein
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CCNB1 mRNA; flumequine promotes the reaction [estragole results in increased expression of CCNB1 mRNA]
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CCND1 mRNA flumequine results in increased expression of CCND1 mRNA
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CCNE1 mRNA; [flumequine co-treated with estragole] results in increased expression of CCNE1 mRNA
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CYP1A2 mRNA; [flumequine co-treated with estragole] results in increased expression of CYP1A2 mRNA
[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in decreased expression of CYP27A1 mRNA; [Sodium Selenite co-treated with Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in decreased expression of CYP27A1 mRNA
[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in decreased expression of CYP7A1 mRNA; Sodium Selenite inhibits the reaction [[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in decreased expression of CYP7A1 mRNA]
[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in decreased expression of GAPDH mRNA; Sodium Selenite promotes the reaction [[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in decreased expression of GAPDH mRNA]
[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in increased expression of GPT protein; Sodium Selenite inhibits the reaction [[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in increased expression of GPT protein]
[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in decreased expression of GPX1 mRNA; Sodium Selenite promotes the reaction [[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in decreased expression of GPX1 mRNA]
[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in increased expression of GPX3 mRNA; Sodium Selenite promotes the reaction [[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in increased expression of GPX3 mRNA]
[Sodium Selenite co-treated with Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in decreased expression of GPX4 mRNA
[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in increased expression of HMGCR mRNA; Sodium Selenite inhibits the reaction [[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in increased expression of HMGCR mRNA]
[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in increased expression of HMOX1 mRNA; [Sodium Selenite co-treated with Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in increased expression of HMOX1 mRNA
[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in increased expression of MT1 mRNA; [Sodium Selenite co-treated with Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in increased expression of MT1 mRNA
[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in increased expression of MT2 mRNA; [Sodium Selenite co-treated with Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in increased expression of MT2 mRNA
[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in increased expression of PFKL mRNA; Sodium Selenite inhibits the reaction [[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in increased expression of PFKL mRNA]
[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in decreased expression of PKLR mRNA; Sodium Selenite promotes the reaction [[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in decreased expression of PKLR mRNA]
[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in decreased expression of SOD1 mRNA; Sodium Selenite promotes the reaction [[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in decreased expression of SOD1 mRNA]
[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in increased expression of SREBF2 mRNA; Sodium Selenite inhibits the reaction [[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in increased expression of SREBF2 mRNA]
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of TNF mRNA; [flumequine co-treated with estragole] results in increased expression of TNF mRNA flumequine results in increased expression of TNF mRNA
flumequine results in decreased expression of UGT2B1 mRNA [flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in decreased expression of UGT2B1 mRNA
1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [Chloroquine results in increased cleavage of CASP3 protein]
1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CEBPB protein alternative form]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [Chloroquine results in increased expression of CEBPB protein alternative form]
1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [Chloroquine results in increased expression of DDIT3 protein] 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [Chloroquine results in increased expression of DDIT3 protein]
1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one results in increased phosphorylation of EEF2 protein
1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [EGFR protein mutant form results in increased expression of FOXG1 mRNA]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [EGFR protein mutant form results in increased expression of FOXG1 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [EGFR protein mutant form results in increased expression of SOX9 mRNA]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [EGFR protein mutant form results in increased expression of SOX9 protein]
1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one promotes the reaction [EIF4EBP1 protein binds to 7-methylguanosine triphosphate] 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one results in decreased phosphorylation of EIF4EBP1 protein
1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [EIF4G1 protein binds to 7-methylguanosine triphosphate]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [EIF4G1 protein binds to PABPC1 mRNA]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [EIF4G1 protein binds to RPL32 mRNA]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [EIF4G1 protein binds to RPS20 mRNA]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [EIF4G1 protein binds to RPS6 mRNA]
1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one results in increased expression of F3 protein
1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [EGFR protein mutant form results in increased expression of FOXG1 mRNA]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [EGFR protein mutant form results in increased expression of FOXG1 protein]
1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[MTOR protein binds to RAPTOR protein] which binds to LARP1 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one promotes the reaction [LARP1 protein binds to PABPC1 mRNA]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one promotes the reaction [LARP1 protein binds to RPL32 mRNA]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one promotes the reaction [LARP1 protein binds to RPS20 mRNA]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one promotes the reaction [LARP1 protein binds to RPS6 mRNA]; LARP1 protein promotes the reaction [1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one results in decreased expression of RPL32 protein]; LARP1 protein promotes the reaction [1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one results in decreased expression of RPS20 protein]; LARP1 protein promotes the reaction [1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one results in decreased expression of RPS6 protein] LARP1 protein results in increased susceptibility to 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one
1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[MTOR protein binds to RAPTOR protein] which binds to LARP1 protein] 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one results in decreased phosphorylation of MTOR protein
1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one results in decreased expression of PABPC1 protein 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [EIF4G1 protein binds to PABPC1 mRNA]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one promotes the reaction [LARP1 protein binds to PABPC1 mRNA]
1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [EIF4G1 protein binds to RPL32 mRNA]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one promotes the reaction [LARP1 protein binds to RPL32 mRNA]; LARP1 protein promotes the reaction [1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one results in decreased expression of RPL32 protein]
1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [EIF4G1 protein binds to RPS20 mRNA]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one promotes the reaction [LARP1 protein binds to RPS20 mRNA]; LARP1 protein promotes the reaction [1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one results in decreased expression of RPS20 protein]
1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [EIF4G1 protein binds to RPS6 mRNA]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one promotes the reaction [LARP1 protein binds to RPS6 mRNA]; LARP1 protein promotes the reaction [1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one results in decreased expression of RPS6 protein]
1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one results in decreased phosphorylation of RPS6KB1 protein
1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[MTOR protein binds to RAPTOR protein] which binds to LARP1 protein]
1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [EGFR protein mutant form results in increased expression of SOX9 mRNA]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [EGFR protein mutant form results in increased expression of SOX9 protein]
1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one results in decreased phosphorylation of TFE3 protein
1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one results in decreased phosphorylation of TFEB protein
1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of TRIB3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [Chloroquine results in increased expression of TRIB3 protein]
1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one results in decreased expression of ULK1 protein
browse the term
